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ABSTRACT
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dient potent orally active, nonneurotoxic anticonvulsant
compounds that are excitatory amino acid and NMDA/
sigma receptor antagonists and that are selected from the
group consisting of those of the formulae:
R3
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wherein R1 is 4-pyridyl or 3-pyridyl, R2 is hydrogen or
methyl and R3 is 3,4»dich1oro, p- or m-chloro, p-bromo.

p-?uoro, p-methyl, p-methoxy or hydrogen. The composi
tions are administered to mammals in an amount to provide

a dosage amount ranging from about 15 mg/kg to 200

mgkg.
22 Claims, 1 Drawing Sheet
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AMINOALKYLPYRIDINE CONIPOUNDS
WHICH ARE USEFUL AS

SUMMARY OF THE INVENTION

It is accordingly one object of the present invention to

ANITCONVULSANT DRUGS, EXCITATORY
AMINO ACID INHIBITORS AND NMDA
SIGMA RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
This invention relates to novel aminoalkylpyridines and
their method of preparation. and more particularly relates to
novel aminoalkylpyridines which are useful as excitatory
amino acid inhibitors and as NMDA/0' (sigma) receptor

provide novel aminoalkylpyridines and their method of

preparation.
It is a further object of the present invention to provide

anticonvulsant agents which comprise aminoalkylpyridines.
10

antagonists and potent orally active antiepileptic pharma
ceutical compositions.

compounds belonging to two series of aminoalkylpyridine

BACKGROUND ART

structures and methods for their use in the treatment of

Epilepsy is a leading neurological disorder. second only to

neurological disorders such as epilepsy and stroke.
A still further object of the present invention is to provide
new aminoalkylpyridines that are inhibitors of the excitatory
amino acid (EAA) neurotransmitter L-glutarnate. The ami
noalkylpyridines of this invention produce a signi?cant
inhibition of the presynaptic release of L-glutamate and also

stroke. One to four million Americans and twenty to forty
million people world-wide suffer from some form of

epilepsy. making it second only to stroke as the leading

neurological disorder. Although standard therapy permits
control of seizures in 80% of these patients, one-half million
people in the U.S. have uncontrolled epilepsy. The number
of drugs useful for the treatment of epilepsy is remarkably
small. Fewer than 20 drugs are currently marketed in the
U.S.. and of these. only ?ve or six are widely used. Complex

partial epilepsy (also known as temporal lobe. psycomotor

act as noncompetitive NMDA antagonists by selectively

inhibiting the speci?c binding of the radioligand [3H]DT G
(ditolylguanidine) to <5 (sigma) receptor sites on the

N-methyl-D-aspartate (NMDA) receptor complex in the
25

or limbic epilepsy). the most devastating form among adults,

oral route and contain as the essential ingredient certain
30

increasingly evident that signi?cant progress toward com
plete control can be achieved only by an understanding of
the mechanisms of the epilepsies themselves. which will

aminoalkylpyridines and use of these aminoalkylpyridines
as potent orally active nonneurotoxic antiepileptic drugs in
the treatment of convulsive disorders such as epilepsy.

Other objects and advantages of the present invention

provide the molecular basis for antiepileptic drug design and
development. and new treatment strategies. Out of the

brain.

A still further object of the present invention is to provide
anticonvulsant compositions which are highly active by the

and estimated to account for an many as two-thirds of all

cases, is refractory to drug treatment (Gummit. R. J., ‘The

Epilepsy Handbook. The Practical Management of
Seizures”. Raven Press. New York. 1983). It is becoming

A further object of the present invention is to provide a
method for the treatment of convulsive disorders by admin
istration of an effective amount of the aminoalkylpyridines
of this invention.
A further object of the present invention is to provide

35

twenty or so new drugs that are in clinical trial in the U.S.,

only a few have been developed based on the knowledge of

include use of the aminoalkylpyridines in the treatment of
stroke and other neurological disorders such as Alzheimer’s
disease. by virtue of their action as noncompetitive NMDA
antagonists and as inhibitors of the excitatory neurotrans

mitter L-glutamate.
In satisfaction of the foregoing objects and advantages.

epilepsy mechanisms (Dichter. M. A.. Epilepsia, 30,

S3-Sl2, 1989).
NMDA receptor overstimulation by high levels of the

there are provided by this invention aminoalkylpyridine

excitatory amino acid (EAA), L-glutamate, has been impli
cated in epileptogenesis and epilepsy (Cavalheiro, et al.,

compounds may be characterized by the following general

“Frontiers in Excitatory Amino Acid Research”, A. R. Liss,
New York. 1988). Thus. development of agents that are
EAA/NMDA antagonists may constitute novel and eifective
therapies for the epilepsies. Although a number of excitatory
amino acid (EAA) inhibitors have been discovered, many

compounds which are useful as anticonvulsant drugs. These

formulae:
45

lack NMDA receptor speci?city and are too toxic for clinical

studies (Porter. Epilepsia. 30. $29-34. 1989). Thus. the
discovery of this invention of certain aminoalkylpyridines as
a superior class of anticonvulsant agents in the Applicant’s

50

methyl and R3 is 3.4-dichloro, p-or m-chloro, p-bromo.
p-?uoro, p-lower alkyl. p-lower alkoxy or hydrogen.

laboratories is signi?cant. The aminoalkylpyridines of this
invention are potent, orally active. nonneurotoxic NMDA

antagonists that hold promise for commercial development
as nontoxic. clinically useful antiepileptic drugs. They can

wherein R1 is 4-pyridyl or 3-pyridyl. R2 is hydrogen or

55

provide the basis for the design of safer NMDA antagonists

Also provided by this invention are orally active, nontoxic
anticonvulsant compositions comprising as the active
ingredient, a compound selected from those of the following
formulae:

with increased potency and reduced toxicity for the man

agement of epilepsy in humans.
Certain aminoalkylpyridines are known to the art as

described in U.S. Pat. Nos. 4.358.446. 3522.262. and 3,654,
290. Aminoalkyl-3-pyridines are described in U.S. Pat. No.
4,358,446 as intermediates in the preparation of certain

N-acylarninoalkyl-3-pyridine derivatives that have activity
as fungicides. U.S. Pat. Nos. 3.522.262 and 3.654290.
describe aminoalkylpyridines as intermediates for prepara
tion of certain indole derivatives which have antiallergic

activity.

wherein R1 is 4-pyridyl or 3-pyridyl. R2 is hydrogen or
methyl and R3 is 3.4-dichloro. p- or m-chloro. p-bromo,
65

p-?uoro, p-lower alkyl, p-lower alkoxy or hydrogen.
Also provided are methods for administration of the
anticonvulsant compositions of this invention to mammals

5 ,648,369
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including animals and humans in the treatment of convulsive

In a third aspect of this invention, there are provided

disorders such as epilepsy including partial and generalized

aminoalkylpyridine compounds of the formulae:

seizures.

BRIEF DESCRIPTION OF THE DRAWING

Reference is now made to the drawing accompanying the

application which is a graph showing the inhibitory eifect of
the aminoalkylpyridines of the invention on endogenous
glutamate release.

wherein R1 is 4-pyn'dyl or 3-py1idyl, R2 is hydrogen or
10

DESCRIPTION OF PREFERRED
EMBODIMENTS

sites on the NMDA receptor complex and also impair the
release of L-glutamate, the excitatory amino acid neu

As indicated above, this invention relates to several new

compounds belonging to two groups of
aminoalkylpyridines, which are useful as antiepileptic
agents. One group of aminoalkylpyridines of this invention
are l-anilino-l-pyridylethans when R2 is methyl, and the

rotransmitter. Thus, new aminoalkylpyridine compounds of
the above formulae are noncompetitive NMDA antagonists
and 0 receptor blockers (Choi, Cerebrovas. Brain Metab.

Revs. 2, 105-147, 1990). These aminoalkylpyridine com

second group of aminoalkylpyridines are l-anilino-l

pyridylmethans when R2 is hydrogen. The aminoalkylpy
ridines of this invention are substituted in the l-position of

pounds of the above formulae are also useful in the treatment
20

the alkyl moiety by a 4-pyridyl or 3-pyridyl group and also
by an anilino group (aminophenyl group) and this in turn
also contains substituents. The alkyl moiety comprises a
one-carbon methyl or two-carbon ethyl group. The ami

noalkylpyridine compounds of this invention have potent
oral anticonvulsant activity as antiepileptic drugs in the

25

treatment of convulsive disorders such as epilepsy including

partial seizures and generalized seizures.
In one aspect of the present invention, two groups of

compounds are provided which have potent oral antiepti
leptic activity and which are of the following general
formulae:
HH

30

35

In the above formulae, R2 is hydrogen or methyl and leads
to the two groups of arninoalkylpyridines. When R2 is
hydrogen, R1 is 4-pyridyl and R3 is 3.4-dichloro, p- or

45

p-bromo, p-?uoro, p-methyl, p-methoxy, or hydrogen.

also as neuroprotective agents in other neurological disor

unique class of noncompetitive NMDAreceptor antagonists,
50

their methods of preparation, and compositions for their use
as a novel class of antiepileptic drugs in the treatment of
convulsive disorders such as epilepsy including partial and

generalized seizures.
55

HH

NMDA receptor overstimulation by glutamate is implicated
in epileptogenesis and epilepsy. Thus, NMDA antagonists

ders.
This invention relates to novel, new and previously
unknown (5 (sigma) selective aminoalkylpyridines, as a

In a second aspect of the invention, there are provided
novel anticonvulsant compositions which are orally active
and nontoxic, and which comprise as the active ingredient an
eifective amount of a compound selected from those of the

following formulae:

selves. [P. K. Kadaba, US. Pat. Nos. 4,511,572; 4,618,681;
4,689,334; 4,610,994; 4,820,721]. Work on the aminoalky
lpyridines indicate they are nontoxic, and highly effective by
the oral route, with protective indices greater than 20. They
impair presynaptic release of L-glutamate and also function
as noncompetitive NMDA (N-methyl-D-aspartate) antago
nists that inhibit with great selectivity and speci?city, the
sigma receptor, but show no af?nity for PCP receptors.

nontoxic, orally active NMDA antagonists developed from
aminoalkyl heterocycles, have good potential for commer
cial application as clinically useful antiepileptic drugs and

m-chloro, p-bromo, p-?uoro, p-methyl, p-methoxy, or

Those compounds wherein R1 is 4—pyridyl, R2 is methyl or
hydrogen and R3 is 3,4-dichloro, p- or m-chloro, p-bromo,
p-?uoro, p-methyl, p-methoxy or hydrogen are new and
novel compounds.

of stroke and Alzheimer’s disease, by virtue of the action of
the above aminoalkylpyridines as inhibitors of L-glutamate
release and as noncompetitive NMDA antagonists.
Studies by the Applicant on the metabolism and pharma
cology of triazoline anticonvulsants, led to the evolution and
discovery of the aminoalkyl heterocycles as a unique class
of anticonvulsant agents, superior to the triazolines them

also provide prophylaxis and seizure protection. There is a
de?nite need for safer, orally active NMDA antagonists, to
afford effective therapies for the epilepsies. Excessive levels
of glutamate are suspected not only in epilepsy, but in
several other neurological disorders, eg. stroke. 'Ihus,

R2

hydrogen. When R2 is methyl, R1 can be 4-pyridyl or
3-pyridyl and R3 can be 3,4-dichloro, p- or m-chloro,

methyl, and R3 is 3,4-dichloro, p-chloro, m-chloro, p-bromo,
p-?uoro or hydrogen. These compounds selectively inhibit
the speci?c binding of [3H]DtI‘G to the <5 (sigma) receptor

Considerable evidence has accrued in the last decade and
a half implicating amino acids in chemical neurotransmis

sion; while GABA (gamma-aminobutyric acid) and glycine

R3

serve as inhibitory neurotransmitters, L-glutarnate and
L-aspartate function as excitatory neurotransmitters in the
central nervous system [Foster. A. C. and Fagg, G. E. Brain
Res. Rev. 7, 103 (1984)]. There exist considerable data that

suggest excitatory amino acids (EAAs) may be critically
wherein R1 is 4-pyridyl or 3-pyridyl, R2 is hydrogen or
methyl and R3 is 3,4—dichloro, p- or m-chloro, p-bromo,

involved in both epileptogenesis and as a focus for 1116

mechanism of action of anticonvulsants (Meldrum, B. S.,

p-?uoro, p-methyl, p-methoxy. or hydrogen.
There are further provided by this invention methods for
administration of the anticonvulsant composition to mam
mals including animals and humans.

65

and Chapman, A. G., In “Glutamine, Glutamate, and GABA
in the Central Nervous System,” L. Hertz, et. al., Ed., Alan
R. Liss, Inc., New York 1983, pp. 625-641; R. Schwarcz and
Yehezkel-Ben-Ari, Eds. “Excitatory Amino Acids and

5,648,369
5

6

Epilepsy”, Plenum Press. New York, 1986). Because brain

receptor antagonists can be separated into two major groups,

function in the normal state is a dynamic balance of exci
tatory and inhibitory processes, one would think that exces

competitive and noncompetitive. The competitive NMDA
antagonists are usually long chain amino acids of low lipid
solubility and poor blood brain barrier penetration and
compete for binding at glutamate recognition sites on the
NMDA receptor complex [Honore. T.. Med. Res. Rev., 9. 1
(1989)]. The noncompetitive NMDA antagonists. on the
other hand. comprise a variety of different lipid soluble
structures that include ketamine, phencyclidine. benzomor
phan “(s opiates” and MK-801. These compounds associate
with the PCP site within the NMDA receptor activated
membrane channel and thus impede cation Ca2+ ?ow
through the channel [Choi. D. W., Cerebrovas. Brain Metab.

sive neuronal activity leading to seizures may result from
either an increase in excitatory transmission. or, alternately,
from a decrease in inhibitory transmission. Thus, effecting
changes in the concentrations of either excitatory or inhibi
tory neurotransmitters at their synapses would represent
potential mechanisms of anticonvulsant action and strategies

for anticonvulsant drug design.
Strong evidence exists for the prominent role of EAAs in
excitatory transmission along limbic circuits which are
believed to be particularly relevant to kindling epileptoge
nesis. More recently, evidence for a causal connection

Revs., 2, 105-147 (1990)]. Thus, by de?nition. the sigma

between EAA release and onset of hyperactivity has been

provided by the use of speci?c EAA receptor antagonists in
various models of epilepsy [Watkins. J. C.. and Evans, R. H.
Ann. Rev. Pharmacol. ToxicoL, 21, 165 (1981)]. There is
mounting evidence that the excitatory neurotransmitters,
L-glutamate and L-aspartate, play a key role in the spread of
epileptic activity from one brain region to another and may
also be contributing to its initiation (Meldrum. B. S., In

20

interact with the NMDA receptor and that of the triazoline
structure to impair presynaptic release of L-glutamate. are
both retained to the full extent or better in the aminoalky

“Handbook of Experimental Pharmacology: Antiepileptic
Drugs.” H. H. Frey and D. Janz Ed, Berlin. 1984). EAA
agonists are convulsants and EAA antagonists show anti
convulsant activity in a variety of seizure models.
EAA Neurotransmitter Systems and the NMDA Receptor
Ionophore Complex. Recent attention has focused on the

25

role of EAAs and the NMDA receptor in health and disease.

[Cavalheiro, E. A.. Lehmann. J.. and Turski. L. Eds.. “Fron
tiers in Excitatory Amino Acid Research”, A. R. Liss, New
York. N.Y.. 1988; Cotrnan, C. W.. et al., J. NIH Res., 1, 65
(1989); Dingledine, R. et al., CRC Crit. Rev. NeurobioL, 4,
1 (1988); Johnson. G.. Ann. Rep. Med. Chem, 24, 41
(1989)]. The postsynaptic actions of L-glutarnate are
believed to be mediated by at least three receptor subtypes

lpyridines. Receptor binding studies indicate that while the
general site of activity of the aminoalkylpyridines is still
con?ned to the PCP receptor sites, the speci?city and
selectivity. unlike that of the [i-amino alcohol. are no longer
at the MK-801 sites. but shifted toward the 0' receptor sites

30

of the PCP receptors.
The compounds of the present invention are useful in

pharmaceutical compositions using conventional pharma
ceutical carriers or vehicles for administration to humans

and animals in unit dosage forms. such as tablets. capsules,
35

pills, powders. granules. suppositories, sterile parenteral
solutions or suspensions. sterile non-parenteral solutions or
suspensions, oral solutions or suspensions, oil in water or

named after the prototypical agonists N-methyl-D-aspartate
(NMDA). kainate (KA) and quisqualate (QA). Although

water in oil emulsions and the like. containing suitable

NMDA itself is not present in the brain. endogenous

L-glutarnate has the highest a?inity for the NMDA receptor.

selective aminoalkylpyridines may function as noncompeti
tive NMDA antagonists.
The aminoalkylpyridines constitute a unique class of
triazoline metabolite analogues; unlike the hydrophilic
B-amino alcohol/ot-amino acid metabolites of tiiazolines,
these hydrophobic metabolite analogues are potent orally
active anticonvulsant agents. Furthermore. neurochernieal
studies indicate that the ability of the ?-amino alcohol to

quantities of the active ingredient.
40

The arninoalkylpyridines of this invention may be pre

The NMDA receptor is the best characterized of the three
EAA receptor subtypes. A group of unusual characteristics

pared by reaction of pyridine aldehydes. when R2 is
hydrogen. or acyl pyridines. when R2 is methyl. ethyl or

sets the NMDA receptor apart from other glutamate
receptors, among them, a high Ca2+ conductance, a slow
onset of the response. and. most important. a voltage

phenyl. with anilines and reduction of the resulting novel
intermediate irnines with sodium borohydride as shown in
4-5

Equation 1.

dependent Mg2+ blockade of the ionic channel gated by the
NMDA receptor. Furthermore. NMDA receptors are asso

ciated with. and in?uenced by, three additional types of
binding sites. a PCP (the anesthetic and psychotomimetic
drug phencyclidine) binding site that is located within the

50

receptor-associated ion channel. thereby blocking channel
conductance. a strychnine-insensitive glycine binding site
that is distinct from the inhibitory glycine receptor of the
spinal cord and a polyarnine recognition site [Williams K.,
Romano. C., and Molinoff, P. R., Mal. PhamuzeoL, 36. 575
(1989)]. Several convincing arguments exist to support the
concept that PCP receptors may constitute three subreceptor
sites. MK-80l. PCP and 0' sites, each with a high degree of

55

selectivity and speci?city to the respective ligands, MK-80l.
TCP (a PCP analogue with a thienyl group in place of the
phenyl) and DTG.
NMDA receptor overstimulation by high levels of
L-glutamate has been implicated in epileptogenesis and
epilepsy. NMDA receptor antagonists that block the action
of L-glutarnate, and thus the overstimulation of the NMDA
receptor. may represent novel antiepileptic agents that can
a?ord both prophylaxis as well as seizure protection. NMDA

In the above equation. R1. R2 and R3 are as de?ned above.
In the method of preparation, the reaction between the
pyridine aldehydes or ketones and anilines is carried out by

condensing the appropriate aniline and pyridine aldehyde or
65

ketone, in an organic solvent such as an aromatic hydrocar
bon which can be benzene, toluene and xylene. The reaction
is conducted at an elevated temperature ranging from about

5,648,369
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50° C. to the boiling point of the solvent used optionally
under pressure. Preferably the reaction is conducted in the

TABLE 1

presence of a catalyst such as an aluminosilicate catalyst

Melting point,

including commercially available molecular sieves.

Imine Prepared

After formation of the imine by this reaction, the reduc
tion to the aminoalkylpyridines is carried out preferably

(1) from 3,4-dichloroaniline
and 4-acetylpyridine
(2) from 4-chloroaniline

using an alcoholic solvent and a reducing agent such as

sodium borohydride. The reaction is conducted with agita
The following examples are presented to illustrate the

80-825

and 4-acetylpyridine
(4) from 4-bromoaniline

157-1595

and 4-acetylpy1idine
(5) from 4-?uoroaniline

the examples and throughout the speci?cation, parts are by
weight unless otherwise indicated.

133-135

and 4-acetylpyridine
(6) from p-toluidine
and 4-acetylpyridine
(7) from p-anisidine
and 4-acetylpyridine

EXAMPLE 1

Preparation of 1-(anilino)-1-(pyridyl)-ethans (1

anilino-l-ethylpyridines)

end of the reaction, the molecular sieves were ?ltered,
washed with benzene and the combined ?ltrates rotary
evaporated to remove xylene. The syrupy residual material
was crystallized from benzene or benzene-petroleum ether
mixture to yield the pure irnines in yields varying from 40%

162-165

(3) from 3-chloroaniline
10

invention, but it is not to be considered as limited thereto. In

(a) Preparation of the imines:
A mixture of the appropriate acetylpyridine (0.06 mol)
and aniline (0.06 mol) in xylene (150 ml) was re?uxed for
4 hours in the presence of molecular sieves (75 g) (Davison,
grade 514, effective pore size 4A, 8-12 mesh beads). At the

102-104

and 4-acetylpyridine

tion at a temperature of from 60° C. up to the boiling point
of the solvent used. The product is then recovered as a solid.

“C.

20

80-82
111-113

(8) from aniline

81-845

and 4-acetylpyridine
(9) ?om 4-chloroani1inc
and 3-acetylpyridine

72-74

TABLE 2
25

Melting
Point, uC.

Yield, %

(1) 1-(3,4-Diclomanilino)-l-

153-1555

68

(2) 1-(4-Chloroanilino)-l-

104-106

79

(3) 1-(3-Chloroanilino)-1-

156-158

80

described procedure are given in Table 1 along with their

(4) 1-(4-Bromoanilino)-1-

107-108

34

melting points.

(5) l-(4-Fluoroanilino)-1-

85-87

60

(6) 1-(4-Methylanilino)-1-

93-955

72

(4-Py1'idYD-ethm1

(4-Py1‘idY1Hth?n

to 60%

(4-PY1‘idyD-eman

The imines that were prepared according to the above

(b) Sodium borohydride reduction of imines. To a solution
of the imine (0.03 mol) in ethanol (100 ml) was added

(4-pyridyliethan
(4-Pyridy1Hthan

35

(4-Py1‘1dyl)-¢than

?nely powdered sodium borohydride (0.15 mol) and the

(7) 1-(4-Methoxyani1ino)-l-

74.5-76

70

126-128

60

121-123

63

(4-Py?dy1>¢m

reaction mixture re?uxed with magnetic stirring for 2-4

(8) 1-(Anilino)-l-(4-pyridyl)-

hours.
The reaction mixture was then cooled in ice and the

ethan

(9) 1-(4-Chloroanilino)-1-

excess sodium borohydride was destroyed by slow addition
of dilute hydrochloric acid (1:1 mixture), until the reaction

(3-pyridylletban

(10) 1-(3,4-Dichloroanilino)-1-

99-1015

31

(11) 1-(4-Chloroanilino)-1-

91-94

26

(12) 1-(3-Chloroanilino)-1-

82-84

18

(13) 1-(4-Bromoanilino)-1-

92-945

32

(l4) 1-(4-Flmroanilino-1-

67-70

33

(15) l-(4-Methylanilino)-1-

71-73

38

74.5-76

33

(4-pyridyl)-methan

mixture was acidic and no more hydrogen evolution was

noticed. The white inorganic solids that precipitated were
dissolved by addition of water and the solution made basic
to sodium hydroxide. It was then cooled in the refrigerator

Compound

(4-pyn'dyl)-methan

45

for 1-2 days, when the l-anilino-l-ethylpyridines appeared

(4-pyridyl)-methan
(4-pyridyl)-methan

as white to beige colored solids. They were ?ltered, washed

well with water, and recrystallized from acetone-petroleum
ether mixture or te111'ary-butyl methyl ether and petroleum
ether mixture. In Table 2, melting points and yields are given
for all the new l-(anilino)-l-(pyridyl)-ethan compounds

(4-pyridyl)-methan
(4-pyridyl)-methan

(16) 1-(4-Methoxyanilino)-1-

(4-pyridyl)-methan

prepared.
EXAMPLE 2

The compounds in Table 1 and Table 2 were identi?ed
55

through their elemental analyses, melting points, and NMR
spectra (for Table 2 compounds) which show a characteristic
doublet of a quartet for the CH proton, when R2 is methyl
and a simple doublet of the CH2 group when R2 is hydrogen,
in the 4.3-4.5 5 region.

Preparation of 1-(anilino)-1-(py1idyl)-methans

(anilino methylpyridines)
(a) Preparation of the imines. A mixture of the pyridine
aldehyde (0.05 mol) and aniline (0.05 mol) in ethanol was
heated on a steam bath, when the irnine appeared as a

EXAMPLE 3

solid mass which was crystallized from ethanol-water

The aminoalkylpyridine compounds and the resulting
orally e?’ective anticonvulsant compositions of this inven

mixture. [Kadaba, P. K., J. Heterocycl. Chem, 12, 143

(1975)].
(b) Sodium borohydride reduction of the above imines was
carried out according to the procedure described for the

preparation of the l-anilino-l-ethylpyridines.

65

tion are useful in the treatment of convulsive disorders. The
oral potency of the compounds range from those which are

very highly potent to those of good medium potency, with no

accompanying toxicity. A series of aminoalkylpyridines of

5,648,369
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this invention has been evaluated for anticonvulsant activity

pounds are placed in one of three categories. Those failing

The potent activity of the aminoalkylpyridines in the MES
test is of great signi?cance, because drugs used in the
treatment of the two major types of seizures (partial and
generalized) are quite distinct in their clinical effects. They
also fall into two pharmacological classes even though
seizures may be induced experimentally by a wide variety of
methods. The clinical aspects of certain generalized
seizures. especially absence seizures, are highly correlated
with experimental seizures produced in the scMet model.
Likewise, partial seizures in humans correlate positively
with experimental seizures elicited by the MES test (Porter.

to demonstrate anticonvulsant activity at doses up to 300

R. J.. and Pitlick. W. H., In “Basic and Clinical

mg/kg are considered inactive. Class II compounds show
anticonvulsant activity at doses greater than 100 mgkg or
show activity at 100 mg/kg which is not reinforced by
similar activity at 300 mg/kg. Thus, compounds of class or
group 11 demonstrate anticonvulsant activity without signs

Pharmacology”, 4th Ed.. B. G. Katzung Ed., Appleton &
Lange. C. A.. 1989. pp. 287-303).

by the intraperitoneal (i.p.) and by the oral (p.o.) route using
two standard seizure models in the mouse and in the rat, the

maximal electroshock seizure (MES) test and the subcuta
neous pentylenetetrazol (Metrazole) seizure threshold
(scMet) test. These two methods of seizure provocation
reliably elicit well characterized seizure phenomena and
together they have been shown su?icient to identify all
compounds known to demonstrate anticonvulsant activity in
other tests [Porter, R. J., et al., Cleveland Clinic Quarterly.
51. 293 (1984)]. Based on the screening results. the com

10

TABLE 3

of neurological de?cit, but do not have signi?cant potency.

Percent

The Class I compounds are those which are most promising
as anticonvulsants. They demonstrate anticonvulsant activ
ity in either the MES test or the scMet test, or both at doses

Compound

of 100 mg/kg or 30 mg/kg without signs of neurological
de?cit and this have an estimated protective index of greater
than 1.
Neurotoxicity is determined by the rotorod ataxia test in
mice and by the positional sense test and gait and stance test
in the rat.
The following Table 3 presents the results of these anti
convulsant tests with respect to several compounds of the
present invention. This Table 3 identi?es the speci?c com

protection*

Classi?-

at 50 rug/kg dose,

cation

p.o., in the MES

(i.p. mouse)

Test in the rat

I

—

I

75-100

I

50-75

I

75-100

I

75-100

I

——

I

25-50

1

50-75

I

25-75

I

50

I

50-100

I

>50

I

>50

I

25

I

—

I

-

(1) l-(3,4-Dic1oroanilino)-l-

(4-pyrldyl)~ethan

25

(2) l-(4-Cloroanilino)-l-

(4-pyridyl)-ethan
(3) l-(3-Chloroanilino)-1-

(4-pyridyl)-ethan
(4) l-(4-Bromoani1ino)-l-

(4-pyridyl)-ethan
(5) 1-(4-Flmroanilino)-1-

(4-pyridyl)-ethan

pounds tested by chemical name and provides the route of
administration, the animal species used, and the anticonvul
sant activity based on classi?cation in Group I or Group II.
when intraperitoneally administered, and based on percent

ASP Group

(6) l-(4-Methylanilino)-1-

(4-Pyridy1)*¢m
(7) l-(4-Methoxyanilino)-1-

(4~pyridyl)-ethan

35

protection. when orally administered.

(s) 1-(Anilino)-1-

As shown in Table 3. all the aminoalkylpyridine com
pounds belong to Class I and demonstrate anticonvulsant
activity at doses of 30 mg/kg to 100 mg/kg. without signs of
neurological de?cit. The anticonvulsant activity of the com
pounds is far more pronounced in the MES test than in the
scMet test. in both mice and rats. by the i.p. and oral routes
of administration. and protective indices greater than 20 are
obtained by oral administration in the rat.
Anticonvulsant quanti?cation in mice. i.p.. for 6 com

(9) 1-(4-Chloroanilino)-l-

(4-pyridyl)-ethan

pounds (Table 4) further con?rms the greater potency of the
aminoalkylpyridines in the MES test; in the scMet test,
protection is obtained only at high dose levels nearing toxic
doses. Anticonvulsant quanti?cation in rats, p.o. (Table 5)

(3-pyridyl)-ethan
(10) 1-(3,4-Dichloroanilino-1-

40

(4-pyridyl)-methan
(l1) 1-(4-Chloroanilino)-1-

(4-pyridyl)-methan
(12) 1-(3-Chloroani1ino)-1-

(4-pyridyl)-methan
(13) l-(4-Bromoanilino)-l-

45

(4-pyridyl)-metl1an
(14) l-(4-F1uoroani1ino-l-

(4-pyridyl)-metl1an
(15) 1-(4-Methylanilino)-1-

(4-pyridy1)-rnethan
(16) 1-(4-Methoxyanilino)-l-

50

(4-pyridyl)-methan

clearly shows that the aminoalkylpyridines, as a class. are
inelfective in the scMet test, but evince a remarkably high

degree of anticonvulsant activity by the oral route in the
MES seizure model, with R1. values >20.

*Number of animals protected/number of animals tested is de?ned as percent

protection.

TABLE 4
Anticonvulsant Quanti?cation in Mice. i.p.

Time of

(2)
(a)

EDSD, mgilig

TDso

rug/kg

RI.“1

Compound

Test (11)a

MES

ScMet

(rotorod)

MES

l-(4-Chloroanilino)-l-

0.25, 0.25

53.71

<150

160.11

2.98

(4-pyridyl)-ethan

0.25

(51.61-57.34)“

1-(3-Chloroanilino)-1-

1, 1

[31.40 i‘ 9.80]°
95.45

(130.8’7-18759)
>250

[9.81 i 2.95]
>500

>524

5,648,369
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TABLE 4-continued
Anticonvulsant Qugti?cation in Mice, ip.
Tme of
Compolmd

(4-pyn'dyl)-ethan
(4)

(5)

Test (h)a

MES

24

(7199-1133)
[8.50 i 296]

l-(4-Bromoanilino)-l-

4, 4

62.74

(4-pyridyl)-ethan

0.25

(50.60-80.48)
[5.42 i 1.56]

1-(4-Fluoroanilinol)-1-

(4-pyridyl)-ethan

T1350
mg/kg

P1.d

ScMet

(rotorod)

MES

>200

>200

>3.19

141.1

2.46

ED“. m?g

0.25, 0.5

57.42

0.25

(50.94-66.55)

>80

(117.5-171.9)

[12.36 i 3.67]
(8)

l-(Anilin0)-l-

4-pyridyl)-ethan

0.5, 0.5

81.74

0.25

(72.94-96.81)

<i00

161.0

l-(4-ChloroanilinO)-1-

(4-pyridy1)-methan

0.5, 0.5

[6.84 i

68.43

106.9

(63.16-76.43)

(80.28—140.10)

[20.43 i 6.81]

[6.07 i- 1.58]

0.25

1.97

(125.8-1949)

[11.17 i 3.55]
(11)

[9.55 i
3.04]

<225

2.05]

6.3

"Tune of test is given in the order for MES, scMet, and rotorod

b( ) 95% con?dence interval
°[ ] Slope, regression line i standard error
"P1. = TDSOIED5o

sant compositions of this invention may be administered in
TABLE 5

pill form or by injection. As indicated above, the dosage rate
ranges from about 15 mg/kg up to about 200 mg/kg.
Screening Methodology to Determine Anticonvulsant
Activity: In mice, i.p.: All compounds are solubilized in
0.5% methylcellulose. The solvent has been tested for anti

Anticonvulsant {@tj?cation in Rat, 2.0.
Time

of
Compound

TDso

Test

EDS“, mg/_1_<g

(h)"

MES

(2) 1-(4-Chloro- 2, 2,

22.89

minim-1- 0.25

(14.40-32.70)b

(4-pyridyl)- thru

[3.17 i 1.19]°

ethan

ScMet

mg]

Pr.‘l

kg

MES

>250

>470 >20.53

>250

>500 >23.93

convulsant and toxic eifects and found to introduce no
35

24

(4) 1-(4-Bromo- 4, 4,

20.89

anilino1)-1- 1
(4-pyridyl)-

(16.76-26.13)
[6.88 i 2.43]

The Maximal Electroshock Seizure Test (MES): Maximal
electroshock seizures are elicited with a 60 Hz alternating
current of 50 mA intensity in mice and about 150 mA in rats
(5-7 times that necessary to elicit minimal electroshock

ethan

(5) 1-(4-F1uoro- 0.5,

81.06

ani1ino)-l- 0.5,

(53.82-1325)

(4-pyridy1)- 0.25

[2.94 i 0.99]

ethan

1-(4-

48.40

0.5,

(33.12-77.60)

pyridy1)-

0.25

[3.61 i 1.23]

ethan

thru
24

(11) l-(4-Chloro- 4, 4,

>500

>6.17

seizures), delivered for 0.2 sec via corneal electrodes. A drop
of 0.9% saline is instilled in the eye prior to application of
the electrodes in order to prevent the death of the animal.
Abolition of the hind limb tonic extension component of the

>250

>500 >10.33

seizure is de?ned as protection and results are expressed as

number of animals protected/number of animals tested.
39.14

a11111J10)-1- 0.25

(24.30-58.65)

(4-pyridy1)- thru

[2.85 i 0.74]

methane

>250

thru
24

(8)1-(Anilino)- 0.5,

signi?cant bias into the testing of anticonvulsant activity.
The compounds are administered intraperitoneally in a vol
ume of 0.01 ml/gm to male CarWorth Farms #1 mice
weighing about 20 gm. All compounds are tested at least at
three dose levels (30, 100 an 300 mglkg) at 30 minutes and
4 hours after their administration.

>250

The Subcutaneous Pentylenetetrazol (Metrazole) Seizure

>500 >12.8

Threshold Test (scMet): A 0.5% solution of 85 mg/kg of
pentylenetelrazol is administered subcutaneously in the pos
terior midline. The animal is observed for 30 minutes.
Failure to observe even a threshold seizure (a single episode

24

'Iime of test given in the order for MES, scMet, and rotorod

b( ) 95% con?dence interval

of clonic spasms of at least 5 sec duration) is de?ned as
protection and the results are expressed as number of

c[ ] Slope, regression line 1 standard error

animals protected/number of animals tested.
Neurotoxicity is evaluated in mice by the rotorod ataxia

The anticonvulsant compounds of the present invention

may be administered to animals or humans at doses ranging 60 test The animal is placed on a Wooden rod of 1V8" diameter
from about 15 mg/kg up to about 200 mg/kg. Preferred
rotating at 6 rpm. Normal mice can remain on a rod rotating

levels of administration range from about 15 mg/kg up to
100 mg/kg. The active ingredients or compounds of this
invention may be administered in any desired form by
injection or in the oral form. Conventional adjuvents and
carriers may be employed in combination With about 0.001
to 2.0 wt. % of the active ingredient. Thus, the anticonvul

at this speed inde?nitely. Neurologic toxicity is de?ned as
the failure of the animal to remain on the rod for 1 minute

and is expressed as number of animals exhibiting toxicity/
65

number of animals tested.

Anticonvulsant Quanti?cation in Mice, i.p.: The EDS0
values are determined in the MES, scMet and rotorod ataxia

5,648,369
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test. To determine the ED50 values, ?ve logarithmically

general. antieptileptic drugs effective against MES seizures

spaced doses of the test compound are administered to
animals in groups of ten, to cover 0-100% protection, and

alter ionic transport across excitable membranes [Porten R.
J ., and Pitlick. W. H., In “Basic and Clinical Pharmacology”,

the dose required to protect 50% of the animals (EDSO)
together with its 95% con?dence limits, are determined

pp. 287-303]. Based on this rationale, the aminoalkylpy

4th Edn., B. G. Katzung, Ed.. Appleton and Lange. CA 1989.

graphically.

ridines may be expected to attenuate EAA neurotransmis

Anticonvulsant Quanti?cation in Rats p.o.: Substances
which exhibit unusual potential as possible antieptileptic
drugs, as determined from all prior testing will be subjected
to anticonvulsant activity test in the rat (Sprague-Dawley

sion. Indeed, evaluation of potential displacement activity of
#2 at all inhibitory and excitatory amino acid receptor types

and subtypes using appropriate radioligands, indicate that
this arninoalkylpyridine inhibits at 10 1.1M concentration.
49% of the binding of [3H]DTG, a ligand highly speci?c for
the <5 (sigma) receptor population of the PCP receptors on
the NMDA receptor-ionophore complex (Table 6). It shows
no activity at the [3H]MK-8O1- or [sHlTCP-binding receptor
sites of the PCP receptor. The aminoalkylpyridine (#2) also
inhibits Ca2+ dependent, K+ evoked release of endogenous

strain). This species will be subject of the complete anti
convulsant quanti?cation test evaluation as described above.
but after oral (gavage) administration of the candidate

compound. These results will permit the critical comparison
of the anticonvulsant activity and neurotoxicity of the agent
under study with similar data previously obtained in mice.
Substances which exhibit potential antiepileptic activity will
be advanced for toxicity and selected pharmacology studies.
Neurological de?cit in rats is examined by the positional

L-glutamate in guinea pig cerebrocortical slices to an extent
of 74% at 50 M and 80% at 100 pM concentrations,

comparable to the parent ADD17014 (Table 6). Because

sense test and gait and stance test. In the positional sense 20 aminoalkylpyridines in general are highly effective in the
MES seizure model, these compounds. as a class can be
test, one hind leg is gently lowered over the edge of a table,

whereupon the animal will quickly lift it back to normal
position. Inability to do so rapidly indicates a neurologic
de?cit. In the gait and stance test, a neurologic de?cit is
indicated by a circular or zigzag gait. ataxia. abnormal

expected to be effective antagonists of NMDA-receptor
mediated EAA neurotransrnission. The ability of the ami
noalkylpyridines to selectively inhibit the 0 receptor sites, in
25

spread of the legs, abnormal body posture. tremor,
hyperactivity, lack of exploratory behavior, somnolence,

offers potential for their use as noncompetitive NMDA

antagonists to afford protection against epilepsy,
particularly, partial seizures including complex partial sei

stupor, or catalepsy.
EXAMPLE 4

zures where there is a de?nite need for more effective drugs,
30 as discussed earlier.

EAAs are lmown to play important roles in excitatory
neurotransmission in partial seizures as discussed earlier.

The Therapeutic Potential of Aminoalkylpyridines as

Clinically Useful Antiepileptic Drugs: Potent Orally Active.

Evaluation of potential displacement activity of aminoalky
lpyridine compounds 1, 2, 3, 4, 5, 6, 8. 9. 10. 11. 12 and 13
at all inhibitory and excitatory amino acid receptor types and

Nonneurotoxic Anticonvulsant Agents: The aminoalkylpy
ridines have evolved as a result of studies on the metabolism
35

subtypes using appropriate radioligands, according to

the blood brain barrier. In screening experiments using
animal seizure models. they show a high degree of anticon
vulsant activity by the oral route with no attendant

neurotoxicity, and with P1. values >20. When compared
with the respective parent triazolines, the aminoalkylpy
ridines appear to be superior anticonvulsant agents (see
Table 8 for comparison of data). Unlike the rigid. closed ring
structures of the triazolines and aziridines. the ?exible, open
45

Thus. several aminoalkylpyridines of this invention are

effective antagonists of NMDA-receptor mediated EAA
neurotransmission and function as noncompetitive NMDA

antagonists and thus can be used to advantage in epilepsy.
stroke and Alzheimer’s disease.
Aminoalkylpyridines Attenuate EAA Neurotransmission:
Role as Noncompetitive NMDA Antagonists: There are

several approaches to antagonizing glutamate-mediated
excitatory processes. and glutamate neurotoxicity. Based on
Choi’s speculative consideration of glutamate neurotoxicity
as a sequential three-stage process—induction, ampli?ca
tion and expression—a range of measures might be used to
protect neurons from excitotoxic damage. since each step of
the neurotoxic process is speci?cally amenable to therapeu
tic interference [Choi, D. W., Cerebrovas. Brain Metab.

Revs., 2. 105-147 (1990)]. Blockade of induction. i.e.
overstimulation of glutamate receptors inducing intracellu
lar accumulation of cazl'. might be accomplished most easily

by antagonizing postsynaptic glutamate receptors, as also by
reducing glutamate release from presynaptic terminals.
EAAs are known to play important roles in excitatory
transmission in partial seizures as discussed earlier. In

and pharmacology of the 1,2.3-triazoline anticonvulsants.
They are highly lipophilic molecules that can readily cross

known procedures indicated that aminoalkylpyridines
inhibit selectively the binding of [3H]DTG, a ligand highly
speci?c for the o (sigma) receptor population of the PCP
receptors on the NMDA receptor-ionophore complex
(Weber et al., Proc. Nat. Acad. Sci.. 83, 8784 (1986)]. They
show no activity at the [3HlMK-801- or [3H]TCP-binding
receptor sites of the PCP receptor. The aminoalkylpyridines
also inhibit Ca2+ dependent. K‘“ evoked release of endog
enous L-glutamate in guinea pig cerebrocortical slices.

addition to impairing presynaptic release of L-glutamate.

structures of the aminoalkylpyridines show inhibitory activ
ity at postsynaptic NMDA receptors while also fully retain
ing the ability of the parent to impair presynaptic release.
TABLE 6

50

Inhibition of speci?c binding of radioligands at
EAA - recc tors b amin

Receptor!

Radio

Reference

Selectivity

ligand

Compound

l-4-

‘dine #2

Reference

Percent Inhibition
(Averagez N = 2)

55

Ki (nM) 104M 1.0_$M

Adenosine
Adenosine
Amino Acids

MECA

39.50

—15.2

—15.9

Excitatory
Glycine
Kainate
NIX-801
65 NMDA
PCP

FHJglycine

D-Alanine

[3H]KA
[3HJMK-8O1
[3H]CGS 19755
[3I-l'jTCP

Kainic Acid
MK-SOl
CPP
PCP

4900.00

8.7

—4.0

24.93
4.30
359.00
62.30

—3.7
13.5
3.5
—3.8

—7.3
17.0
—6.6
—1.8

5,648,369
15

16

TABLE 6-continued

TABLE 8-continued

Inhibition of speci?c binding of radioligands at

classi?cation, active

EAA - receptors by aminQlsylA-pg'dine (#2)

at 300 mg/kg only)

classi?wl?on
ac?ve at 100

Class 11 (ASP

rug/kg)
Class I (ASP

5

Refer- Percent Inhibition
Receptor!

Radio

Selectivi

Reference

ligand

Compound

ence

4-OCH3

Avera e' N = 2

AMPA
Haloperidal

11.80
11.50

4.2
12.9

4.3
49.1

BenzodlaZePlm

Clonazepam
_

3.40

-4.7

-7 .8

gg‘g:

18:51:13’!

Glycine

Stryc] .

Inhibitory

protection at

Class 11 (ASP

48.40

so ins/kg
H

[3H]AMPA
[3H]DTG

25-50%

active up to 300 mg/kg)

Ki (nM) 1O"7M 1.04M

ty

Quisqualate
Sigma

classi?cation, I10!

17:38

2':

31 50

_1.8

10

classi?cation, active
at 300 mg/kg only)

This invention has been described herein with reference to
certain preferred embodiments. However, as obvious varia

15 tions thereon will become apparent to those sln'lled in the art,
_1.4

the mvennon 1s not to be considered as limited thereto.

Nitrate

What is claimed is:

1. A compound of the following formulae:
Values are expressed as the percent inhibition of speci?c binding and

represent the average of duplicate tubes at each of the concentrations tested. 20

1?: ]|-[

R3

R1 —? —N
R2

TABLE 7

Inhibi?m °f L'glutamate release by ADD17O14 and

25 wherein R1 is 4-pyridyl, R2 is hydrogen or methyl and R3 is

l-(4-chloroanilino)-l-ethyl-4-pyridine (#2)

p_methyl or p_methoxyl

E?ects of drugs: Results are shown on the attached ?gure and in the

2. A compound according to claim 1 wherein R2 is methyl

table below. All results are means 1 SEM of n = 4 independent

exPemnents Pel'fm'med “1 'nPhcate-

Release of endogenous gluatamate in the presence of ADD17014 and #2

and R3 is p-methyl.

3. A compound according to claim 1 wherein R2 is methyl

30 and R3 is _methoxy

and 30 mM K", signi?cantly di?erent from e?’ects of K1’ alone

(P < 0.001)
Treatment

p

'

.

.

.

2 .

4. A compound according to claim 1 wherem R is
hydrogen and R3 is p'methyl2

Release (% basal)

5. A compound according to claim 1 wherein R is
basal 2 +

108 i 2

2311151554

184 i 10

—50 PM (basal)
50 PM (I?)

101i 9
136 i 6

100 1.1M (basal)
100 1.1M (14*)

109 i 4
122 t 5

50 M (basal)
50 M (K*)
100 11M (basal)
100 11M (16)

101 i 6
121 i 8
99 i 9
114 i 4

Aminoalkylpyridine #2

hydrogen and R3 is p-methoxyl.

35

6. A potent orally active, nonneurotoxic anticonvulsant
composition comprising as the active ingredient, an anti
convulsant eifective amount of a compound selected ?'om
the group consisting of those of the formulae:

40

H H

l

|

R3

R 1_C_
| N
R2

45 wherein R1 is 4-pyridyl. R2 is hydrogen or methyl and R3 is
p-methyl or p-methoxy, and a pharmaceutical carrier.
7. A comp osition according to claim 6 wherein R1 is

TABLE 8

4-pyridyl, R2 is methyl and R3 is p-rnethyl.

Comparison of Anticonvulsant E?icacy of Triazounes with
Aminvalkylpyridines in the MES Test, Rat. 1m

8. A composition according to claim 6 wherein R1 is
50 4-pyridyl, R2 is methyl and R3 is p-methoxy.

9. A composition according to claim 6 wherein R1 is
4-pyridyl, R2 is hydrogen and R3 is p-methyl.
10. A composition according to claim 6 wherein R1 is

X

N0

1'“

4-py11'dyl, R2 is hydrogen and R3 is p-methoxy.

N

55

N/

11. A potent orally active, nonneurotoxic anticonvulsant
composition comprising as the active ingredient, an anti
convulsant effective amount of a compound of the formulae

ADD17014

Nee-Ne
(‘1 13
x

6“

R2
wherein R1 is 4-pyridyl, R2 is methyl and R3 is p-chloro, and

4.C1

26576

2239

4-CH3

Class 11 (ASP

Class I (ASP

65 a pharmaceutical carrier.

12. A potent orally active, nonneurotoxic anticonvulsant
composition comprising as the active ingredient, an anti

5,648,369
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convulsant effective amount of a compound of the formulae
H H

l

17. An EAA inhibitor and noncompetitive NMDA

antagonist/6 receptor blocker composition according to
claim 16, wherein R1 is 4-pyridylt R2 is methyl and R3 is

R3

I

p-chloro.

R1—(|:-N
R2

18. An EAA inhibitor and noncompetitive NMDA

antagonist/0' receptor blocker composition according to
claim 16, wherein R1 is 4-pyridyl, R2 is methyl and R3 is

wherein R1 is 3-pyridyl, R2 is methyl and R3 is p-chloro, and

p-methyl.

a pharmaceutical carrier.

13. A composition according to claim 6 wherein a suffi
cient amount of the effective ingredient is contained in said

10

19. An EAA inhibitor and noncompetitive NMDA

antagonist/o receptor blocker composition according to
claim 16. wherein R1 is 3-pyridyl, R2 is methyl and R3 is

composition to provide a dosage amount ranging from about
15 mg/kg to 200 mg/kg.

p-chloro.

14. A method for the treatment of convulsive disorders in
mammals which comprises administration thereto of an

20. An imine of the formula:

effective dosage amount of an anticonvulsant composition of

R3

claim 6.
15. A method according to claim 14 wherein the compo
sition is administered in a dosage amount ranging from

about 15 mg/kg to 200 mg/kg of body weight
16. An inhibitor of excitatory amino acid (EAA) neu

wherein R1 is 4-pyridyl or 3-pyridy1. R2 is hydrogen or

rotransmission which comprises inhibition of L-glutamate
release and NMDA/sigma receptor blocking, comprising an
effective amount of a compound of the following formulae:
HH

R3

R2

wherein R1 is 4-pyridyl or 3-pyridyl. R2 is hydrogen or
methyl and R3 is p-methyl or p-chloro and a pharmaceutical
carrier.

methyl. and R3 is 3.4-dichloro. p-chloro, m-chloro, p-bromo,
p-?uoro. p-lower alkyl. p-lower alkoxy or hydrogen.
25

21. An imine according to claim 20 wherein R1 is

4-pyridyl. R2 is methyl and R3 is 3,4-dichloro, p-chloro,
m-chloro, p-bromo, p-?uoro. p-methyl. p-methoxy or hydro
gen.
22. A composition according to claim 6 wherein the active
ingredient is contained in the composition in an amount of
0.001 to 2.0 wt. %.

